We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00687492
First Posted: May 30, 2008
Last Update Posted: December 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) [ Time Frame: After collecting all Patient Record Form. ]

Secondary Outcome Measures:
  • The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. [ Time Frame: After collecting all Patient Record Form. ]
  • The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. [ Time Frame: After collecting all Patient Record Form. ]
  • The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. [ Time Frame: After collecting all Patient Record Form. ]

Estimated Enrollment: 8000
Study Start Date: May 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Criteria

Inclusion Criteria:

  • 2 or more risk factors (according to NCEP ATP III guideline)
  • Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion Criteria:

  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study.
  • Participation in a clinical study during the last 90 days.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00687492


  Show 59 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Park Jeong Euy Sungkyunkwan University
  More Information

Responsible Party: Joher Raniwalla, AstraZeneca
ClinicalTrials.gov Identifier: NCT00687492     History of Changes
Other Study ID Numbers: NIS-CAP-DUM-2008/1
First Submitted: May 28, 2008
First Posted: May 30, 2008
Last Update Posted: December 2, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
hypercholesterolemia
NCEP ATP III guidelines
survey

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases